TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0470nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0750nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0770nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0910nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.100nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.110nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.110nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.110nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.120nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.140nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.140nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.160nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.190nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.210nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.240nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.290nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.330nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.400nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.400nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.530nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.960nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 2.30nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 2.5nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 5.20nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 6.10nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 7.60nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 11nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 11nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 14nMAssay Description:The kinase selectivity was assessed by profiling Example 1 in a 442-kinase panel (386 non-mutant kinases) at a concentration of 1 μM using the K...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 15nMAssay Description:Selected compounds were also tested for their binding properties against FLT3 kinase mutants using suitable in vitro assays (performed according to s...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 15nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 46nMAssay Description:Selected compounds were also tested for their binding properties against FLT3 kinase mutants using suitable in vitro assays (performed according to s...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 55nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 82nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 130nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 130nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 590nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 670nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 730nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 810nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 830nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 1.00E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 1.80E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 2.80E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 3.00E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 3.20E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
